Compugen begins dosing in ovarian cancer trial

Compugen (CGEN) announced that the first patient was dosed in the global randomized sub-trial 1 of adaptive platform trial, MAIA-ovarian evaluating maintenance therapy with single agent COM701, a potential first-in-class anti-PVRIG antibody in patients with relapsed platinum sensitive ovarian cancer. An interim analysis of sub-trial 1 of MAIA-ovarian is planned to take place in the second half of 2026. Compugen believes positive data could inform a registration path for COM701 monotherapy and an opportunity to combine COM701 with other agents, broadening COM701’s opportunities within the ovarian cancer population.